CD30 and CD40 are members of the tumor necrosis factor (TNF) receptor family. These two receptors have pleiotropic biologic functions including induction of apoptosis and enhancing cell survival. This review will discuss the pattern of expression of these receptors in malignant lymphoid disorders and their prospective ligands. Understanding issues related to these two ligands and their receptors in lymphoid malignancies may help to improve the classification of these diseases and could open the doors for new treatment strategies.
SteinH., GerdesJ., SchwabU.Evidence for the detection of the normal counterpart of Hodgkin and Sternberg-Reed cells.Hematol Oncol a1983; 1: 21–9.
2.
DurkopH., LatzaU., HummelM., EitelbachF., SeedB., SteinH.Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease.Cell1992; 68: 421–7.
3.
SmithC.A., GrussH.J., DavisT.CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF.Cell1993; 73: 1349–60.
4.
SteinH., MasonD.Y., GerdesJ.The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.Blood1985; 66: 848–58.
5.
ClarkE.A., LedbetterJ.A.Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50.Proc Natl Acad Sci USA1986; 83: 4494–8.
6.
PaulieS., Ehlin-HenrikssonB., MellstedtH., KohoH., Ben-AissaH., PerlmannP.A p50 surface antigen restricted to human urinary bladder carcinomas.Cancer Immunol Im-munother1985; 20: 23–8.
7.
StamenkovicI., ClarkE.A., SeedB.A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas.Embo J1989; 8: 1403–10.
8.
ArmitageR.J., FanslowW.C., StrockbineL.Molecular and biological characterization of a murine ligand for CD40.Nature1992; 357: 80–2.
9.
ArmitageR.J., SatoT.A., MacduffB.M.Identification of a source of biologically active CD40 ligand.Eur J Immunol1992; 22: 2071–6.
10.
GrussH.J., DowerS.K.Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas.Blood1995; 85: 3378–404.
11.
ChiarleR., PoddaA., ProllaG., GongJ., ThorbeckeG.J., InghiramiG.CD30 in normal and neoplastic cells.Clin Immunol1999; 90: 157–64.
12.
de BruinP.C., GrussH.J., van der ValkP., WillemzeR., MeijerC.J.CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications.Leukemia1995; 9: 1620–7.
13.
D'EliosM.M., RomagnaniP., ScalettiC.In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells.J Leukoc Biol1997; 61: 539–44.
14.
Del PreteG., MaggiE., PizzoloG., RomagnaniS.CD30, Th2 cytokines and HIV infection: a complex and fascinating link.Immunol Today1995; 16: 76–80.
15.
Del PreteG., De CarliM., AlmerigognaF.Prefer-ential expression of CD30 by human CD4+ T cells producing Th2– type cytokines.Faseb J1995; 9: 81–6.
16.
RomagnaniP., AnnunziatoF., ManettiR.High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus.Blood1998; 91: 3323–32.
17.
FaliniB., PileriS., PizzoloG.CD30 (Ki-1) mole-cule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.Blood1995; 85: 1–14.
18.
ChanJ.K., NgC.S., HuiP.K.Anaplastic large cell Ki-1 lymphoma. Delineation of two morphological types.Histopathology1989; 15: 11–34.
19.
DelsolG., Al SaatiT., GatterK.C.Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis.Am J Pathol1988; 130: 59–70.
20.
GreerJ.P., KinneyM.C., CollinsR.D.Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma.J Clin Oncol1991; 9: 539–47.
21.
InghiramiG., MacriL., CesarmanE., ChadburnA., ZhongJ., KnowlesD.M.Molecular characterization of CD30+ anaplastic large-cell lymphoma: high frequency of c-myc pro-to-oncogene activation.Blood1994; 83: 3581–90.
KaudewitzP., SteinH., DallenbachF.Primary and secondary cutaneous Ki-1+ (CD30+) anaplastic large cell lymphomas. Morphologic, immunohistologic, and clinical characteristics.Am J Pathol1989; 135: 359–67.
24.
PileriS.A., PiccalugaA., PoggiS.Anaplastic large cell lymphoma: update of findings.Leuk Lymphoma1995; 18: 17–25.
25.
CarboneA., GloghiniA., GaidanoG., Dalla-FaveraR., FaliniB.BCL-6 protein expression in human peripheral T-cell neoplasms is restricted to CD30+ anaplastic large-cell lymphomas.Blood1997; 90: 2445–50.
26.
CabanillasF., ArmitageJ., PughW.C., WeisenburgerD., DuvicM.Lymphomatoid papulosis: a T-cell dyscrasia with a propensity to transform into malignant lymphoma.Ann Int Med1995; 122: 210–7.
27.
OudejansJ.J., DukersD.F., JiwaN.M.Expression of Epstein-Barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV.J Clin Pathology1996; 49: 897–902.
28.
ReynoldsD.J., BanksP.M., GulleyM.L.New characterization of infectious mononucleosis and a phenotypic comparison with Hodgkin's disease.Am J Pathol1995; 146: 379–88.
29.
HorieR., WatanabeT.CD30: expression and function in health and disease.Semin Immunol1998; 10: 457–70.
30.
PizzoloG., RomagnaniS.CD30 molecule (Ki-1 Ag): more than just a marker of CD30+ lymphoma.Haematologica1995; 80: 357–66.
31.
LatzaU., FossH.D., DurkopH.CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule.Am J Pathol1995; 146: 463–71.
32.
Horn-LohrensO., TiemannM., LangeH.Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4).Int J Cancer1995; 60: 539–44.
33.
PizzoloG., VinanteF., ChilosiM.Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage.Br J Haematol1990; 75: 282–4.
34.
NadaliG., TavecchiaL., ZanolinE.Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome.Blood1998; 91: 3011–6.
35.
PizzoloG., VinanteF., NadaliG.High serum level of soluble CD30 in acute primary HIV-1 infection.Clin Exp Immunol1997; 108: 251–3.
36.
OkumuraM., HidakaY., KurodaS., TakeokaK., TadaH., AminoN.Increased serum concentration of soluble CD30 in patients with Graves’ disease and Hashimoto's thyroiditis.J Clin Endocrinol Metab1997; 82: 1757–60.
37.
GiacomelliR., CiprianiP., LattanzioR.Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease.Clin Exp Immunol1997; 108: 42–6.
38.
GerliR., MuscatC., BistoniO.High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints.Clin Exp Immunol1995; 102: 547–50.
39.
FattovichG., VinanteF., GiustinaG.Serum levels of soluble CD30 in chronic hepatitis B virus infection.Clin Exp Immunol1996; 103: 105–10.
40.
NadaliG., VinanteF., AmbrosettiA.Serum levels of soluble CD30 are elevated in the majority of untreat-ed patients with Hodgkin's disease and correlate with clinical features and prognosis.J Clin Oncol1994; 12: 793–7.
41.
ZinzaniP.L., PileriS., BendandiM.Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients.J Clin Oncol1998; 16: 1532–7.
42.
YounesA., ConsoliU., SnellV.CD30 ligand in lymphoma patients with CD30+ tumors.J Clin Oncol1997; 15: 3355–62.
43.
GrussH.J.Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily.Int J Clin Lab Res1996; 26: 143–59.
44.
ClodiK., YounesA.Reed-Sternberg cells and the TNF family of receptors/ligands.Leuk Lymphoma1997; 27: 195–205.
45.
GrussH.J., HerrmannF.CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.Leuk Lymphoma1996; 20: 397–409.
46.
YounesA., ConsoliU., ZhaoS.CD30 ligand is expressed on resting normal and malignant human B lymphocytes.Br J Haematol1996; 93: 569–71.
47.
PintoA., AldinucciD., GloghiniA.Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line.Blood1996; 88: 3299–305.
48.
GrussH.J., PintoA., GloghiniA.CD30 ligand expression in nonmalignant and Hodgkin's diseaseined lymphoid tissues.Am J Pathol1996; 149: 469–81.
49.
GrussH.J., DaSilvaN., HuZ.B., UphoffC.C., GoodwinR.G., DrexlerH.G.Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.Leukemia1994; 8: 2083–94.
50.
AmakawaR., HakemA., KundigT.M.Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice.Cell1996; 84: 551–62.
51.
ChiarleR., PoddaA., ProllaG., PodackE.R., ThorbeckeG.J., InghiramiG.CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway.J Immunol1999; 163: 194–205.
52.
HeathW.R., KurtsC., CaminschiI., CarboneF.R., MillerJ.F.CD30 prevents T-cell responses to non-lymphoid tissues [In Process Citation].Immunol Rev1999; 169: 23–9.
53.
KurtsC., CarboneF.R., KrummelM.F., KochK.M., MillerJ.F., HeathW.R.Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells.Nature1999; 398: 341–4.
54.
GrussH.J., UlrichD., BraddyS., ArmitageR.J., DowerS.K.Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells.Eur J Immunol1995; 25: 2083–9.
55.
GrussH.J., HirschsteinD., WrightB.Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease.Blood1994; 84: 2305–14.
56.
JungW., KruegerS., RennerC.Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources.Mol Immunol1994; 31: 1329–34.
57.
GrellM., ZimmermannG., GottfriedE.Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF.Embo J1999; 18: 3034–43.
58.
GatteiV., DeganM., GloghiniA.CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin.Blood1997; 89: 2048–59.
59.
PeraM.F., BennettW., CerrettiD.P.Expression of CD30 and CD30 ligand in cultured cell lines from human germ-cell tumors.Lab Invest1997; 76: 497–504.
60.
GrussH.J., HerrmannF., GatteiV., GloghiniA., PintoA., CarboneA.CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues.Leuk Lymphoma1997; 24: 393–422.
61.
van KootenC., BanchereauJ.Functional role of CD40 and its ligand.Int Arch Allergy Immunol1997; 113: 393–9.
62.
BanchereauJ., BazanF., BlanchardD.The CD40 antigen and its ligand.Annu Rev Immunol1994; 12: 881–922.
63.
GrussH.J., HerrmannF., GatteiV., GloghiniA., PintoA., CarboneA.CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues.Leuk Lymphoma1997; 24: 393–422.
64.
YoungL.S., EliopoulosA.G., GallagherN.J., DawsonC.W.CD40 and epithelial cells: across the great divide.Immunol Today1998; 19: 502–6.
65.
WingettD.G., VestalR.E., ForcierK., HadjokasN., NielsonC.P.CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis.Breast Cancer Res Treat1998; 50: 27–36.
66.
GormandF., BriereF., PeyrolS.CD40 expression by human bronchial epithelial cells.Scand J Immunol1999; 49: 355–61.
67.
BanchereauJ., DuboisB., FayetteJ.Functional CD40 antigen on B cells, dendritic cells and fibroblasts.Adv Exp Med Biol1995; 378: 79–83.
CallardR.E., ArmitageR.J., FanslowW.C., SpriggsM.K.CD40 ligand and its role in X-linked hyper-IgM syn-drome.Immunol Today1993; 14: 559–64.
70.
GrewalI.S., FlavellR.A.The role of CD40 ligand in costimulation and T-cell activation.Immunol Rev1996; 153: 85–106.
71.
RathmellJ.C., TownsendS.E., XuJ.C., FlavellR.A., GoodnowC.C.Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor.Cell1996; 87: 319–29.
72.
SpriggsM.K., FanslowW.C., ArmitageR.J., BelmontJ.The biology of the human ligand for CD40.J Clin Immunol1993; 13: 373–80.
73.
De PaoliP., CozziM., TedeschiR.High CD40 membrane expression in AIDS-related lymphoma B cell lines is associated with the CD45RA+, CD45RO+, CD95+ phenotype and high levels of its soluble form in culture supernatants.Cytometry1997; 30: 33–8.
74.
CarboneA., GloghiniA.Diagnostic significance of CD40, CD40L, and CD26 expression in Hodgkin's disease and other lymphomas [letter].Am J Clin Pathol1996; 105: 522–3.
75.
ClodiK., SnellV., ZhaoS., CabanillasF., AndreeffM., YounesA.Unbalanced expression of Fas and CD40 in mantle cell lymphoma.Br J Haematol1998; 103: 217–9.
76.
ClodiK., AsgaryZ., ZhaoS.Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells.Br J Haematol1998; 103: 270–5.
77.
CarboneA., GloghiniA., PintoA.CD40: a sensitive marker of Reed-Sternberg cells [letter].Blood1996; 87: 4918–9.
JakobsonE., JonssonG., BjorckP., PaulieS.Stimulation of CD40 in human bladder carcinoma cells inhibits anti-Fas/APO-1 (CD95)-induced apoptosis.Int J Cancer1998; 77: 849–53.
80.
CarboneA., GloghiniA., GrussH.J., PintoA.CD40 antigen expression on Reed-Sternberg cells. A reliable diagnostic tool for Hodgkin's disease [letter; comment].Am J Pathol1995; 146: 780–1.
81.
CarboneA., WeissL.M., GloghiniA., FerlitoA.Hodgkin's disease: old and recent clinical concepts.Ann Otol Rhinol Laryngol1996; 105: 751–8.
82.
CarboneA., GloghiniA.The role of current and new discriminating markers in the immunodiagnosis of Hodgkin's disease and other phenotypically related lymphomas.Pathologica1996; 88: 169–74.
83.
EliopoulosA.G., DawsonC.W., MosialosG.CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator.Oncogene1996; 13: 2243–54.
84.
HostagerB.S., BishopG.A.Cutting edge: contrasting roles of TNF receptor-associated factor 2 (TRAF2) and TRAF3 in CD40-activated B lymphocyte differentiation.J Immunol1999; 162: 6307–11.
85.
PullenS.S., DangT.T., CruteJ.J., KehryM.R.CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs). Binding site specificity and activation of downstream pathways by distinct TRAFs.J Biol Chem1999; 274: 14246–54.
86.
DevergneO., McFarlandE.C., MosialosG., IzumiK.M., WareC.F., KieffE.Role of the TRAF binding site and NF-kap-paB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression.J Virol1998; 72: 7900–8.
87.
KehryM.R.CD40-mediated signaling in B cells. Balancing cell survival, growth, and death.J Immunol1996; 156: 2345–8.
88.
IzumiK.M., McFarlandE.C., TingA.T., RileyE.A., SeedB., KieffE.D.The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-inter-acting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation.Mol Cell Biol1999; 19: 5759–67.
89.
Ardila-OsorioH., ClausseB., MishalZ., WielsJ., TurszT., BussonP.Evidence of LMP1-TRAF3 interactions in glycosphingolipid-rich complexes of lymphoblastoid and nasopharyngeal carcinoma cells.Int J Cancer1999; 81: 645–9.
90.
EliopoulosA.G., BlakeS.M., FloettmannJ.E., RoweM., YoungL.S.Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2.J Virol1999; 73: 1023–35.
91.
RathmellJ.C., GoodnowC.C.The in vivo balance between B cell clonal expansion and elimination is regulated by CD95 both on B cells and in their micro-environment.Immunol Cell Biol1998; 76: 387–94.
92.
ChoiY.S.Differentiation and apoptosis of human germinal center B-lymphocytes.Immunol Res1997; 16: 161–74.
93.
YounesA., SnellV., ConsoliU.Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia.Br J Haematol1998; 100: 135–41.
94.
WangD., FreemanG.J., LevineH., RitzJ., RobertsonM.J.Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies.Br J Haematol1997; 97: 409–17.
95.
PlankenE.V., WillemzeR., Kluin-NelemansJ.C.The role of the CD40 antigen on malignant B cells.Leuk Lymphoma1996; 22: 229–35.
96.
GrewalI.S., FlavellR.A.The CD40 ligand.At the center of the immune universe? Immunol Res1997; 16: 59–70.
97.
ToesR.E.M., SchoenbergerS.P., van der VoortE.I.H., OffringaR., MeliefC.J.M.CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity.Semin Immunol1998; 10: 443–8.
98.
HessS., EngelmannH.A novel function of CD40: induction of cell death in transformed cells.J Exp Med1996; 183: 159–67.
99.
CarboneA., GloghiniA., GrussH.J., PintoA.CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease.Am J Pathol1995; 147: 912–22.
100.
CarboneA., GloghiniA., ZagonelV.The expression of CD26 and CD40 ligand is mutually exclusive in human T- cell non-Hodgkin's lymphomas/leukemias.Blood1995; 86: 4617–26.
101.
InghiramiG., LedermanS., YellinM.J., ChadburnA., ChessL., KnowlesD.M.Phenotypic and functional char-acterization of T-BAM (CD40 ligand)+ T-cell non-Hodgkin's lymphoma.Blood1994; 84: 866–72.
102.
SchattnerE.J., MascarenhasJ., ReyfmanI.Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity.Blood1998; 91: 2689–2697.
103.
BrownM.P., TophamD.J., SangsterM.Y.Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice.Nat Med1998; 4: 1253–60.
104.
CarayanniotisG., MastersS.R., NoelleR.J.Suppression of murine thyroiditis via blockade of the CD40-CD40L interaction.Immunology1997; 90: 421–6.
105.
SaitoK., SakuraiJ., OhataJ.Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28.J Immunol1998; 160: 4225–31.
106.
KoshyM., BergerD., CrowM.K.Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes.J Clin Invest1996; 98: 826–37.
107.
EarlyG.S., ZhaoW., BurnsC.M.Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response.J Immunol1996; 157: 3159–64.
108.
HolderM.J., WangH., MilnerA.E.Suppression of apoptosis in normal and neoplastic human B lympho-cytes by CD40 ligand is independent of Bc1-2 induction.Eur J Immunol1993; 23: 2368–71.
109.
GhiaP., BoussiotisV.A., SchultzeJ.L.Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival.Blood1998; 91: 244–51.
110.
Voorzanger-RousselotN., FavrotM., BlayJ.Y.Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells.Blood1998; 92: 3381–7.
111.
RomanoM.F., LambertiA., TassoneP.Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells.Blood1998; 92: 990–5.
112.
GrafD., MullerS., KorthauerU., van KootenC., WeiseC., KroczekR.A.A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation.Eur J Immunol1995; 25: 1749–54.
